The Scottish Government recognises the significant impact of Storm Babet on people, businesses and communities. The Government has been working closely with affected local authorities on a package of support to help people whose homes and businesses were flooded. This package includes extending the Bellwin scheme’s application window to help all Councils, including Argyll and Bute, cover eligible expenditure for urgent repairs.

The Scottish Welfare Fund also provides emergency support to those on low incomes in Scotland, including in Argyll and Bute. Support may be provided through the provision of Crisis Grants and Community Care Grants, including to those who have experienced a disaster situation, such as a flood. Residents can apply to the Scottish Welfare Fund through their Council.

This support is in addition to Scotland’s longer-term investment in flood resilience, where we have committed £150m over the course of this Parliament to deliver improved flood resilience, in addition to the £42m provided annually to councils for flood resilience through the general capital grant.

The Nursing and Midwifery Council’s mid-year registration data report covers a six-month period and reflects those with a Scottish address who have registered, it does not indicate actual employment in Scotland’s health sector. The report itself therefore cannot be used as a true reflection of recruitment in Scotland.

Whilst the report shows a 22% increase in registration in Scotland compared to a 27.7% increase in registration across the UK in the last six months relative to the same period last year, nursing and midwifery levels per head of population show that we have 8.4 qualified Nurses and Midwives per 1,000 population, compared to 6.3 in England, 8.2 in Wales and 9.1 in Northern Island. This means nursing and midwifery levels are 32% higher, per head of population in Scotland than in England. Overall Nursing and Midwifery staffing in Scotland is at a record high and remains the best paid across the UK.

The Scottish Government uses a range of measures and sources to consider and report on the impact of the Care Experienced Children and Young People Fund.

Nationally published data, such as the annual Educational Outcomes for Looked after Children is used to consider the impact of this fund. It is encouraging that the latest statistics show an improving position for care experienced children and young people. Whilst real progress has been made, there remains a sizeable gap between the educational outcomes of care experienced children and young people and all pupils. It’s within that context that Scottish Government officials are currently working with local government to develop a long-term approach to improving these outcomes in response to the Promise.

The impact of the Care Experienced Children and Young People Fund is also considered as part of the Evaluation Strategy for the Attainment Scotland Fund 2022 – 2026 . The first annual evaluation plan for 2022-23 , published in February 2023 and, most recently, the SAC Leads Survey Report published 22 September 2023. Evidence from the latter of those shows the Care Experienced Children and Young People Fund is viewed to have supported strategic decision-making to improve attainment or outcomes for care experienced children and young people within respondent local authorities. Dedicated postholders such as Virtual Headteachers were also highlighted for their positive contribution towards joint working and capacity building.

Existing local authority Education Standards and Quality reports (or local equivalent reports) are also used to report on the progress being made with the support of all Attainment Scotland Funding, including the Care Experienced Children and Young People Funding. Within these reports each local authority presents a clear narrative on the extent to which this funding has influenced and supported local approaches to making progress towards identified stretch aims and achieving the mission of the Scottish Attainment Challenge. Many local authorities have also set specific targets for care experienced children and young people in their stretch aims and these are published as part of the aggregated measures .

The National Improvement Framework and Improvement Plan is designed to help us deliver the twin aims of excellence and equity; galvanising efforts and aligning our collective improvement activities across all partners in the education system to address our key priorities. At national level, this Improvement Plan summarises the key evidence and identifies both ongoing and new improvement activity that we will be taking forward or supporting at national level. These plans also play a role in measuring ongoing activity and the impact of this fund.

I have Ministerial portfolio responsibility for access to new medicines in Scotland. Accordingly, as you know, I met with you on 6 December 2023 together with representatives of Scottish cystic fibrosis (CF) families to listen to their concerns directly.

In addition, the Chief Pharmaceutical Officer (CPO) engages with representatives of Quest for a Cure, a patient group who represent Scottish CF families, and the Cystic Fibrosis Trust.

To ensure that people get the financial support that they are entitled to as quickly as possible, adult disability benefit applications from people with a terminal illness in Scotland are fast-tracked. We also ensure that those who are terminally ill automatically receive the highest rates of assistance that they are entitled to, with no award reviews. They are eligible for this support straight away, with no qualifying period.

The new palliative care strategy will seek to understand and respond to the social determinants of people’s experiences towards the end of life, including financial insecurity and housing.

I refer the member to the answer to question S6W-23384 on 11 December 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

My officials engage with the UK Government on a range of medicines-related matters, including the availability of medicines, and keep me updated as required.

As part of work being undertaken to develop the new Palliative Care Strategy, we are gathering and analysing evidence to tell us what actions should be taken to achieve the aim of ensuring that everyone in Scotland receives well-coordinated, timely and high-quality palliative care, care around death, and bereavement support based on their needs and preferences.

We have set up a number of working groups, bringing together stakeholders with expertise in priority areas for action, and these groups are developing recommended actions for inclusion in the strategy for discussion with the Strategy Steering Group (SSG) at its next meeting.

At the September meeting of the SSG there was discussion on the progress of the working groups and work being done to better understand people’s lived experiences of palliative care, as well as the proposed structure and timeline for the Strategy. A minute of the meeting will be available on the SG website, at https://www.gov.scot/groups/palliative-and-end-of-life-care-strategy-steering-group/ , once this has been agreed by the group.

My officials engage with the pharmaceutical industry on a range of matters, including the development of new medicines, and keep me updated as required.

The Chief Pharmaceutical Officer last met with Vertex Pharmaceuticals on 6 December 2023 and continued to impress upon them the importance of offering a revised price to address the concern that the current price of the cystic fibrosis (CF) medicines covered by the multiple technology appraisal (MTA) exceeds what the NHS would consider reasonable. She also discussed the ongoing availability of clinical trial CF medicines, including when a trial is stopped.

The Scottish Government remains committed to supporting people with cystic fibrosis (CF) to benefit from medicines which help them to live fuller lives, for longer. That is why we introduced a memorandum of understanding (MoU) with the manufacturer, Vertex Pharmaceuticals, in 2018. As part of the MoU, there was an expectation that Vertex would resubmit each of their CF medicines to the Scottish Medicines Consortium (SMC) for a health technology appraisal (HTA). To progress this, the SMC is collaborating with the National Institute for Health and Care Excellence (NICE) on a multiple technology appraisal (MTA) of Vertex’s CF medicines, including Kaftrio ® .

While the NICE MTA is ongoing, I can confirm that all existing and new patients in Scotland who are on, or who are started on a CF medicine will continue to have access to that CF medicine after NICE and the SMC issue their final recommendations. This will be irrespective of the outcome of the appraisal and will cover any need to subsequently switch to a different CF medicine.

If any CF medicine is not recommended in the final MTA guidance, clinicians in Scotland will be able to request the use of that medicine on a case-by-case basis for any new patients using the Peer Approved Clinical System (PACS) Tier Two process. National guidance explicitly states that Health Boards should not take account of the cost of medicines when considering applications using the PACS Tier Two system.